Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.

20191 citationsJournal Article

Authors

Stevan Popović · Klinički centar Vojvodine

Darjana Jovanovic

Biljana Mihaljević

Nebojša Andjelković

Goran Marjanović

Dragomir Marisavljević

Abstract

Treatment with rituximab plus chemotherapy is effective in advanced stages of FL. Significant prognostic factors are FLIPI score for induction therapy outcome, CD43 antigen expression for OS and TTP and ECOG performance status for OS.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 22, Issue 2, pp. 487-494

Field-Weighted Citation Impact: 0.00